checkAd
    Matinas BioPharma Holdings Aktie
    0,1700
     
    USD
    -1,73 %
    -0,0030 USD
    Letzter Kurs 18.05.24 NYSE Arca
    0,1700
     
    USD
    100 STK
    Geldkurs 17.05.24
    0,1750
     
    USD
    100 STK
    Briefkurs 17.05.24
    ISIN: US5768101058 · WKN: A2DMQP · SYM: MTNB · USA

    Neueste Nachrichten

    New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
    16.05.24 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
    09.05.24 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting
    07.05.24 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
    02.05.24 · globenewswire · Matinas BioPharma Holdings
    In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
    30.04.24 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma Prices $10 Million Registered Direct Offering
    03.04.24 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
    27.03.24 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
    25.03.24 · globenewswire · Matinas BioPharma Holdings
    Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
    22.03.24 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
    22.03.24 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
    26.02.24 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
    20.02.24 · globenewswire · Matinas BioPharma Holdings